Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
Elevated CAR has been associated with adverse outcomes in many conditions, including cancer, sepsis, COVID-19, and cardiovascular diseases. A higher C-reactive protein to albumin ratio (CAR) is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback